Aravis

Aravis is a Switzerland based venture capital organisation managing two funds focused on life science (Aravis Biotech I & II) and a third fund focused on renewable energy (Aravis Energy I). Since 1995 the Aravis management team have invested over $600 million in more than 80 companies.

As well as providing venture capital backing, Aravis also takes a hands-on approach to highly promising companies offering a unique international network that combines decades of experience in science, operations and financing.

With a disciplined investment process and Aravis' hands on approach in supporting management, the companies that Aravis has invested in have shown a comparatively low failure rate and many have grown to become some of the leading companies in their fields.

News

04.11.09
MerLion Pharmaceuticals Pte Ltd receives IND Approval from the FDA for Finafloxacin; a Novel 'pH Activated' Antibiotic. ...
22.10.09
Evolva raises CHF 28 million in First Closing of Series B
...
07.10.09
Omeros Prices Initial Public Offering of Common Stock at $10.00 Per Share
...
10.09.09
Arpida and Evolva plan merger ...
16.07.09
Evolva successfully completes Phase I Single Ascending Dose Trial on EV-077 for renal and cardiovascular indications ...
© 2008 Aravis SA  |  Lehfrauenweg 10   |  CH 8053 Zuerich  |  Tel. +41 43 499 20 00 | Fax +41 43 499 20 01  |  Disclaimer  |   Developed by Dogbytes Websolutions